A246250 Share Price Performance
₩1,969.00
-1011.00 (-33.93%)
Price ₩1,969.00
Share Price₩1,969.00
A246250 Community Narratives
There are no narratives available yet.
Recent A246250 News & Updates
No updates
SLS BIO Co., Ltd Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.24
- Gross Margin
- 24.44%
- Net Profit Margin
- 0.041%
- Debt/Equity Ratio
- 0%
SLS BIO Co., Ltd Competitors
About A246250
- Founded
- 2007
- Employees
- n/a
- CEO
- WebsiteView website
SLS BIO Co., Ltd develops diagnostic technologies in South Korea. It offers pharmaceuticals quality control testing services, including pharmaceutical equivalence study, raw materials/finished drugs test, and other analysis testing services; and efficacy evaluation services, such as immune function-based efficacy evaluation and pharmacokinetics and toxicokinetics analysis services. In addition, it provides diagnostic kits comprising rapid allergy test, rapid bovine pregnancy diagnosis, and horse individual forensic kits, as well as nano-bio technologies. The company was formerly known as Specialty Lab Solution Co., Ltd. and changed its name to SLS BIO Co., Ltd in July 2017. SLS BIO Co., Ltd was founded in 2007 and is based in Suwon-si, South Korea.
South Korean Market Performance
- 7 Days: -2.0%
- 3 Months: 20.9%
- 1 Year: 26.1%
- Year to Date: 28.6%
Over the last 7 days, the market has dropped 2.0%, driven by losses in the Materials and Information Technology sectors of 7.0% and 1.3%, respectively. As for the longer term, the market has actually risen by 26% in the last year. As for the next few years, earnings are expected to grow by 22% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading